CANDEL THERAPEUTICS INC. - COMMON STOCK

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

23 Apr 2025 16:05:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

01 Apr 2025 08:01:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

26 Mar 2025 16:05:18 By Nasdaq GlobeNewswire

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

20 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

18 Mar 2025 08:00:46 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

13 Mar 2025 16:15:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

25 Feb 2025 08:00:14 By Nasdaq GlobeNewswire

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

13 Jan 2025 08:00:05 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

16 Dec 2024 16:01:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Pricing of Public Offering

12 Dec 2024 23:00:53 By Nasdaq GlobeNewswire

Candel Therapeutics Announces $80 Million Proposed Public Offering

12 Dec 2024 16:51:06 By Nasdaq GlobeNewswire

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

11 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

14 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

07 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

05 Nov 2024 09:00:32 By Nasdaq GlobeNewswire

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

28 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

04 Oct 2024 09:00:45 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

13 Aug 2024 08:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

18 Jun 2024 08:00:00 By Nasdaq GlobeNewswire